The medical world is experiencing enormous advancements due to technological progress, particularly in precision medicine, which enables individually optimized treatments for patients. Nevertheless, there are challenges in putting this advanced medicine into practice, as many patients still receive the wrong medication. This is partly due to inadequate testing of new drugs. The German software company XO Life has taken on this ethical problem. Following the development of the nebenwirkungen.de platform, which enables users to anonymously report intolerances to the manufacturer, XO Life has now created a communication platform that connects patients, doctors, pharmacists and drug manufacturers. It is the first digital exchange platform of its kind in the world.
XO Life's innovative digital real-world evidence platform, which was developed in a two-year collaboration with experts, enables patients to share their experiences with drug treatments anonymously and in real time using a standardized scientific survey process. The collected consumer experiences are recorded in a structured manner in the ImpactMonitor and serve as the basis for personalized risk-benefit profiles of therapies. The adaptive software-as-a-service solution Pharmacoviligance offers medical professionals a modern communication infrastructure that can be extended by telemedicine services and impresses with its seamless data security.
